WO2001018028A8 - Nouveaux estra-1,3,5(10)-trien-3-yl-sulfamates c-13-substitues, procedes de fabrication de ceux-ci et compositions pharmaceutiques contenant ces composes pour l'inhibition d'eostrone sulfatase - Google Patents

Nouveaux estra-1,3,5(10)-trien-3-yl-sulfamates c-13-substitues, procedes de fabrication de ceux-ci et compositions pharmaceutiques contenant ces composes pour l'inhibition d'eostrone sulfatase

Info

Publication number
WO2001018028A8
WO2001018028A8 PCT/EP2000/008374 EP0008374W WO0118028A8 WO 2001018028 A8 WO2001018028 A8 WO 2001018028A8 EP 0008374 W EP0008374 W EP 0008374W WO 0118028 A8 WO0118028 A8 WO 0118028A8
Authority
WO
WIPO (PCT)
Prior art keywords
compounds
sulfamates
triene
novel
producing
Prior art date
Application number
PCT/EP2000/008374
Other languages
German (de)
English (en)
Other versions
WO2001018028A1 (fr
Inventor
Sigfrid Schwarz
Dirk Kosemund
Gerd Mueller
Margit Richter
Olaf Peters
Ina Scherlitz-Hofmann
Thomas Michel
Walter Elger
Gudrun Reddersen
Birgitt Schneider
Original Assignee
Jenapharm Gmbh
Sigfrid Schwarz
Dirk Kosemund
Gerd Mueller
Margit Richter
Olaf Peters
Scherlitz Hofmann Ina
Thomas Michel
Walter Elger
Gudrun Reddersen
Birgitt Schneider
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jenapharm Gmbh, Sigfrid Schwarz, Dirk Kosemund, Gerd Mueller, Margit Richter, Olaf Peters, Scherlitz Hofmann Ina, Thomas Michel, Walter Elger, Gudrun Reddersen, Birgitt Schneider filed Critical Jenapharm Gmbh
Priority to JP2001522251A priority Critical patent/JP2003508542A/ja
Priority to AU77739/00A priority patent/AU7773900A/en
Priority to EP00967631A priority patent/EP1212346A1/fr
Publication of WO2001018028A1 publication Critical patent/WO2001018028A1/fr
Publication of WO2001018028A8 publication Critical patent/WO2001018028A8/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/0072—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the A ring of the steroid being aromatic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/32—Antioestrogens

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne de nouveaux estra-1,3,5(10)-trien-3-yl-sulfamates C13-substitués de la formule générale (I), dans laquelle R1 représente le résidu acyle, oxycarbonyle, aminocarbonyle, sulfonyle ou aminosulfonyle, et R15 représente du C2-C5-alkyle, C2-C5-alcényle ou C2-C5-alkinyle. Ladite invention concerne également les procédés de fabrication de ces composés et les compositions pharmaceutiques contenant ces composés. Les composés selon l'invention de la formule générale (I) inhibent l'activité des stéroïde sulfatases (EC 3.1.6.2) et ne présentent pas d'activité oestrogène.
PCT/EP2000/008374 1999-09-08 2000-08-28 Nouveaux estra-1,3,5(10)-trien-3-yl-sulfamates c-13-substitues, procedes de fabrication de ceux-ci et compositions pharmaceutiques contenant ces composes pour l'inhibition d'eostrone sulfatase WO2001018028A1 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
JP2001522251A JP2003508542A (ja) 1999-09-08 2000-08-28 新規のｃ１３−置換エストラ−１，３，５（１０）−トリエン−３−イル−スルファメート、その製造法および該化合物を含有する医薬品組成物
AU77739/00A AU7773900A (en) 1999-09-08 2000-08-28 Novel c13-substituted estra-1,3,5(10)-triene-3-yl-sulfamates, a method for producing the same and pharmaceutical compositions containing these compounds
EP00967631A EP1212346A1 (fr) 1999-09-08 2000-08-28 Nouveaux estra-1,3,5(10)-trien-3-yl-sulfamates c13-substitues, procedes de fabrication de ceux-ci et compositions pharmaceutiques contenant ces composes

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19943708.4 1999-09-08
DE19943708A DE19943708B4 (de) 1999-09-08 1999-09-08 Neue C13-substituierte Estra-1,3,5(10)-trien-3-yl-sulfamate, Verfahren zu deren Herstellung und diese Verbindungen enthaltende pharmazeutische Zusammensetzungen

Publications (2)

Publication Number Publication Date
WO2001018028A1 WO2001018028A1 (fr) 2001-03-15
WO2001018028A8 true WO2001018028A8 (fr) 2001-06-07

Family

ID=7921778

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2000/008374 WO2001018028A1 (fr) 1999-09-08 2000-08-28 Nouveaux estra-1,3,5(10)-trien-3-yl-sulfamates c-13-substitues, procedes de fabrication de ceux-ci et compositions pharmaceutiques contenant ces composes pour l'inhibition d'eostrone sulfatase

Country Status (5)

Country Link
EP (1) EP1212346A1 (fr)
JP (1) JP2003508542A (fr)
AU (1) AU7773900A (fr)
DE (1) DE19943708B4 (fr)
WO (1) WO2001018028A1 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPWO2001081364A1 (ja) 2000-04-24 2004-01-08 協和醗酵工業株式会社 エストラ−１，３，５（１０）−トリエン誘導体
US8026229B2 (en) 2001-08-13 2011-09-27 Sterix Limited Antitumor-active 2-alkoxyestradiol sulfamates
DE10307104A1 (de) * 2003-02-19 2004-09-23 Schering Ag Antitumor wirksame 2-substituierte Estra-1,3,5(10)-trien-3-yl sulfamate
DE10307103A1 (de) 2003-02-19 2004-09-09 Schering Ag Antitumor wirksame 2-substituierte D-Homostra-1,3,5(10)-trien-3-yl sulfamate
DE10307105A1 (de) * 2003-02-19 2004-09-09 Schering Ag Antitumor wirksame 2-substituierte 18a-Homoestra-1,3,5(10)-trien-3-yl sulfamate

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19540233B4 (de) * 1995-10-19 2005-08-25 Schering Ag Sulfamat-Derivate von 1,3,5(10)-Estratrien-Derivaten, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende pharmazeutische Zusammensetzungen
US5705495A (en) * 1995-10-19 1998-01-06 Jenapharm Gmbh & Co. Kg. Sulfamate derivatives of 1,3,5(10)-estratriene derivatives, methods for their production and pharmaceuticals containing these compounds
DE19712488A1 (de) * 1997-03-25 1998-10-01 Knoell Hans Forschung Ev Steroidsulfamate, Verfahren zu ihrer Herstellung und Anwendung derselben

Also Published As

Publication number Publication date
JP2003508542A (ja) 2003-03-04
DE19943708B4 (de) 2007-12-20
AU7773900A (en) 2001-04-10
DE19943708A1 (de) 2001-03-15
WO2001018028A1 (fr) 2001-03-15
EP1212346A1 (fr) 2002-06-12

Similar Documents

Publication Publication Date Title
RU2196769C2 (ru) Производные аминобензойной кислоты, фармацевтическая композиция
CA2417825A1 (fr) 6.alpha., 9.alpha.-difluoro-17.alpha.-`(2-furanylcarboxyle) oxy!-11.beta.-hydroxy-16.alpha.-methyle-3-oxo-androst-1,4,-diene-17-acide carbothioique s-fluoromethyle ester utilise comme agent anti inflammatoire
CA2222329A1 (fr) Acides phenylboroniques substitues en position 4, utilises comme stabilisateurs d'enzymes
CA2387356A1 (fr) Forme crystalline 0 de clarithromycine
AU575612B2 (en) (piperidine-4-yl-amino)-benzimidazoles/imida-20 pyrines
CA2124932A1 (fr) Inhibiteurs de l'activite des hormones sexuelles steroidiennes
IE881269L (en) Steroids
ATE255589T1 (de) Kristallin form i von clarithromycin
NZ507309A (en) Fatty acid derivatives of bile acids and bile acid derivatives
IE871733L (en) Amides
KR970010784A (ko) 11-(치환된 페닐)-에스트라-4,9-디엔 유도체
IL148426A0 (en) α-HYDROXY ACID DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME
WO1995018821A3 (fr) Composes antiandrogenes, preparations pharmaceutiques associees et leurs modes d'utilisation
WO2001018028A8 (fr) Nouveaux estra-1,3,5(10)-trien-3-yl-sulfamates c-13-substitues, procedes de fabrication de ceux-ci et compositions pharmaceutiques contenant ces composes pour l'inhibition d'eostrone sulfatase
MY128392A (en) 6ALPHA, 9ALPHA-DIFLUORO-17ALPHA-(2-FURANYLCARBOXYL)OXY]-11ß-HYDROXY-16ALPHA-METHYL-3-OXO-ANDROST-1,4,-DIENE-17-CARBOTHIOIC ACID S-FLUOROMETHYL ESTER AS AN ANTI-INFLAMMATORY AGENT
CA2374249A1 (fr) Formulations liquides du dithiocarbamate
IL156811A0 (en) Bisaryl derivatives and pharmaceutical compositions containing the same
WO2001016157A3 (fr) Procede de preparation de derives d'acides biliaires
GR3031118T3 (en) Novel seco-D steroids active in the cardiovascular system and pharmaceutical compositions containing same
CA2010982A1 (fr) Promotion de l'osteogenese par l'utilisation de derives de vitamine d
CA2382106A1 (fr) Steroides, procedes de preparation desdits composes, compositions pharmaceutiques les renfermant, et leurs utilisations
EP1164139A4 (fr) Nouveaux derives du sulforhamnosylacylglycerol et leur utilisation comme medicaments
WO2002026759A3 (fr) 17α-FLUORALKYLSTEROIDES, LEUR PROCEDE DE PRODUCTION ET COMPOSITIONS PHARMACEUTIQUES CONTENANT CES COMPOSES
CA2362903A1 (fr) Nouveaux derives du sulfofucosylacylglycerol et leur utilisation comme medicaments
WO2001030759A3 (fr) Cristaux d'inhibiteurs de l'echangeur sodium-hydrogene de type 1

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: C1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: C1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

CFP Corrected version of a pamphlet front page

Free format text: REVISED TITLE RECEIVED BY THE INTERNATIONAL BUREAU AFTER COMPLETION OF THE TECHNICAL PREPARATIONS FOR INTERNATIONAL PUBLICATION

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
ENP Entry into the national phase in:

Ref country code: JP

Ref document number: 2001 522251

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 2000967631

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2000967631

Country of ref document: EP

WWR Wipo information: refused in national office

Ref document number: 2000967631

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 2000967631

Country of ref document: EP